HPV is not one virus but a family of more than 150 related strains. Around forty of them infect the genital tract, and the rest live on skin elsewhere on the body, causing the everyday warts most people encounter at some point in childhood.

Of the genital strains, doctors split them into two big groups. Low-risk HPV — most famously types 6 and 11 — causes genital warts but almost never cancer. High-risk HPV — types 16, 18, 31, 33, 45, 52, 58 and a handful of others — can change the cells of the cervix, anus, throat, or other tissues if the infection persists for years. Types 16 and 18 alone cause roughly 70 percent of cervical cancers in India.

HPV is dramatically common. More than 80 percent of sexually active adults will encounter at least one strain in their lifetime. Most of these infections are silent and self-clearing — the body's immune system removes the virus within 12 to 24 months without the person ever knowing.

The trouble starts only when a high-risk strain lingers for years. Persistent infection is the bridge between a common virus and a serious cancer, and that bridge usually takes 10 to 20 years to cross — which is exactly the window screening exists to catch.

• HPV spreads through direct skin-to-skin contact with an infected genital area. Vaginal, anal, and oral sex are the main routes, but penetrative sex is not required — close genital contact alone can transmit the virus.
• Rarely, HPV can pass from mother to baby during vaginal delivery and cause a condition called recurrent respiratory papillomatosis. This is uncommon and does not usually require a Caesarean.
• HPV does NOT spread through toilet seats, shared swimming pools, sharing utensils, hugging, kissing on the cheek, mosquito bites, or being in the same room. This is a persistent Indian misconception worth correcting clearly.
• Higher-risk situations include: starting sexual activity young, multiple sexual partners (yours or your partner's), a weakened immune system from HIV, organ transplant, lupus, or long-term steroid use, and smoking, which significantly increases the risk that a high-risk HPV infection will progress to cervical cancer.
• Being in a long-term monogamous relationship lowers your risk but does not eliminate it. HPV can have been carried silently from a partner's earlier life and may appear years later. This is biology, not a moral statement.
• Condoms reduce HPV transmission but do not eliminate it, because the virus lives on skin around the genital area that a condom does not always cover. They still matter — use them — but they are not a substitute for vaccination and screening.

• Genital warts (condyloma) — flesh-coloured, cauliflower-shaped bumps on the vulva, vagina, cervix, penis, scrotum, or anal area. Caused almost entirely by low-risk types 6 and 11. Painless but sometimes itchy; may bleed if rubbed.
• Cervical cancer — the second most common cancer in Indian women, responsible for about 75,000 deaths every year. Almost always caused by persistent high-risk HPV infection.
• Anal cancer — both in women and men, more common in people with HIV or who have receptive anal sex. Mostly driven by HPV 16.
• Cancers of the vulva, vagina, and penis — less common, but a meaningful share of these are HPV-related.
• Oropharyngeal cancer — cancers of the back of the throat, base of the tongue, and tonsils. Driven mainly by HPV 16; the share of throat cancers linked to HPV has been rising worldwide.
• Recurrent respiratory papillomatosis — a rare condition in babies born to mothers with active genital warts, causing wart-like growths in the airway. Treated by paediatric ENT specialists.
• Most people who get HPV will experience none of these. The body clears the virus quietly in 70 to 80 percent of cases.

High-risk HPV is almost always symptomless. There is no rash, no pain, no discharge, no fever, no fatigue. The infection itself causes no warning sign — which is exactly why screening matters so much. By the time symptoms of cervical cancer appear, the disease is usually already advanced.

Low-risk HPV announces itself as genital warts. These are typically small, soft, flesh-coloured to slightly grey bumps on or around the genital or anal area. They can be flat, raised, or cauliflower-shaped, single or in clusters. Most are painless; some itch; they may bleed if scratched, rubbed during sex, or irritated by tight clothing.

If high-risk HPV has already progressed to cervical pre-cancer or cancer, the warning signs that should trigger an urgent gynae visit include: bleeding after sex, bleeding between periods, postmenopausal bleeding, foul-smelling vaginal discharge, persistent pelvic pain, or pain during sex. See bleeding-after-sex-india for a deeper look at one of the most common red flags.

The majority of HPV infections — symptomatic or not — clear on their own within 12 to 24 months. Persistence beyond two years is the pattern that needs medical attention.

• Pap smear — the classic test. A small spatula or brush gathers cells from the surface of the cervix, which are then examined under a microscope for abnormal changes. Recommended every 3 years for women 21 to 65, or every 5 years when combined with HPV testing. Cost in India: roughly 300 to 1,500 rupees in private labs and hospitals.
• HPV DNA test — detects high-risk HPV strains directly in cervical cells, rather than waiting to see cell changes. Now FOGSI-preferred as the primary screening test from age 30 onwards. Cost: roughly 1,500 to 5,000 rupees, depending on lab.
• Colposcopy — a magnified examination of the cervix performed if a Pap or HPV test is abnormal. The gynaecologist applies acetic acid or iodine; abnormal areas turn a different colour and are sampled. Cost: roughly 2,000 to 8,000 rupees in private practice.
• VIA — Visual Inspection with Acetic Acid. A low-cost, single-visit screening method used in India's government cervical cancer screening programme, particularly in rural and primary-care settings. Acetic acid is painted onto the cervix and abnormal areas turn white. Free in government PHCs and CHCs.
• Biopsy — the definitive test. A small piece of tissue is taken and examined by a pathologist to confirm whether changes are mild (CIN 1), moderate-to-severe (CIN 2/3), or invasive cancer.
• Common Indian labs offering HPV-related tests include Thyrocare, Metropolis, SRL, and the in-house labs of Apollo, Fortis, Manipal, Cloudnine, and most major teaching hospitals. Sample collection is straightforward and usually takes less than 10 minutes in the chair.
• There is no separate HPV blood test in routine clinical use. Diagnosis is based on cervical-cell sampling, not a finger-prick or vein-draw. Men currently have no routine HPV screening test — diagnosis in men is usually based on visible warts or symptoms of HPV-related cancer.

• Cervavac — India's first indigenous HPV vaccine, made by the Serum Institute of India and launched in September 2022. Quadrivalent, covering types 6, 11, 16, and 18. Cost: roughly 2,000 to 3,500 rupees per dose at private clinics. By far the most affordable option.
• Gardasil 9 — imported from Merck. Nonavalent, covering types 6, 11, 16, 18, 31, 33, 45, 52, and 58 — pushing cervical-cancer prevention from around 70 percent to around 90 percent. Cost: roughly 3,000 to 5,000 rupees per dose in private practice.
• Cervarix — bivalent (types 16 and 18 only), made by GSK. Less commonly stocked in India now since Cervavac and Gardasil 9 have largely replaced it.
• Dose schedule for ages 9 to 14: two doses, given 6 to 12 months apart. The younger immune system mounts such a strong response that two doses provide protection equivalent to three doses given later.
• Dose schedule for ages 15 to 26: three doses at 0, 1 to 2 months, and 6 months. Indian and international bodies now support extended catch-up vaccination up to age 45 after a shared-decision conversation with your gynaecologist; the benefit is smaller but still meaningful, because most adults have only been exposed to a few HPV strains, not all of them.
• The vaccine is most effective before sexual debut, but is still worthwhile after it. Government rollout is gradually expanding — Sikkim, parts of Punjab, Maharashtra, Karnataka, and others have run free school-based programmes — but most Indian families currently access HPV vaccination through private paediatricians and gynaecologists.
• For a deeper guide on Cervavac vs Gardasil 9, dose schedules, side effects, and cost-by-state, see The HPV Vaccine in India: Cervavac, Gardasil, and What Every Family Should Know.

• Topical creams — imiquimod 5 percent (brand names such as Imiquad, Aldara) and podophyllin or podofilox solutions are applied directly to the warts at home over several weeks. Cost: roughly 1,500 to 4,000 rupees per course. Should be prescribed by a doctor; not for use during pregnancy.
• Cryotherapy — freezing the warts with liquid nitrogen in the clinic. Quick, effective, often takes 2 to 4 sessions spaced a few weeks apart. Cost: roughly 500 to 2,500 rupees per session.
• Electrocautery — burning the warts off with a small heated probe under local anaesthetic. Used for larger or stubborn warts. Cost: roughly 1,000 to 4,000 rupees per session.
• Surgical excision — cutting the warts out, typically reserved for very large lesions or those that have not responded to other treatments. Cost: roughly 3,000 to 8,000 rupees per session.
• Laser treatment — sometimes used in specialist dermatology or gynaecology centres for resistant cases. Cost: roughly 2,000 to 5,000 rupees per session.
• Treatment removes the visible warts but does not eliminate the underlying HPV from the body. Recurrence within a few months is common; further sessions may be needed until the immune system fully clears the virus.
• Warts during pregnancy are usually treated conservatively, often after delivery, because some treatments are unsafe in pregnancy and warts may shrink on their own postpartum. Caesarean is not automatically required.

• CIN 1 (mild cellular changes) — usually monitored every 6 to 12 months with repeat Pap or HPV testing, as most CIN 1 regresses on its own without treatment.
• CIN 2 or CIN 3 (moderate to severe changes) — treated to remove the affected tissue before it becomes invasive cancer.
• LEEP (Loop Electrosurgical Excision Procedure) — the most common precancer treatment in India. A thin wire loop heated by electric current removes the abnormal cervical tissue under local anaesthetic. Done as a day procedure. Cost: roughly 3,000 to 15,000 rupees.
• Cone biopsy — a deeper, cone-shaped removal of cervical tissue, used when LEEP is not sufficient or to get a more complete diagnosis. Done in theatre, sometimes under general anaesthetic. Cost: roughly 10,000 to 30,000 rupees.
• Cryotherapy of the cervix — freezing abnormal cells with liquid nitrogen. Less commonly used than LEEP today, but still an option in government programmes and rural settings. Cost: roughly 1,500 to 5,000 rupees.
• Laser ablation — using a focused laser beam to destroy abnormal cervical tissue. Available in select centres. Cost: roughly 8,000 to 20,000 rupees.
• If cancer has developed, treatment depends on stage and may involve surgery (including radical hysterectomy), radiation, chemotherapy, or a combination, under the care of a gynaecological oncologist. Ayushman Bharat PMJAY covers cervical cancer treatment at empanelled hospitals; check eligibility at your district hospital or online portal.

A positive HPV test is not a cancer diagnosis. In 70 to 80 percent of people, especially women under 30, the immune system clears the virus naturally within 1 to 2 years without any treatment. No medication speeds this up; the body handles it quietly.

About 20 to 30 percent of high-risk HPV infections persist beyond two years. Persistence — not initial infection — is what raises the cancer risk. The longer a high-risk strain stays in the cervical cells, the greater the chance it will gradually change those cells into precancer and eventually cancer over 10 to 20 years.

Factors that make persistence and progression more likely include smoking, HIV infection, long-term immune-suppressing medication, and persistent infection with the highest-risk strains 16 and 18.

If your HPV test is positive but your Pap is normal, your gynaecologist will typically recommend repeating the HPV test in 12 months. If both stay positive or cell changes appear, colposcopy is the next step. This is a standard surveillance pattern, not an emergency.

HPV does not cause infertility directly. Some precancer treatments such as deep cone biopsy may slightly increase the risk of preterm birth in a future pregnancy, which is why treatment is matched carefully to severity — only as much tissue is removed as is medically needed.

• Annual gynaecology check-up, with screening on the schedule recommended by your doctor — Pap every 3 years or HPV DNA every 5 years from age 30 onwards.
• Do not smoke. Smoking significantly increases the risk that a high-risk HPV infection will progress to precancer or cancer. This is one of the most modifiable risk factors.
• Look after your immune system: balanced meals with plenty of vegetables and protein, regular sleep, regular movement, and active stress management. The immune system does the actual work of clearing HPV.
• Use condoms with new or non-monogamous partners. They reduce HPV transmission, lower the risk of other infections, and remain a basic part of sexual health, even if they cannot block HPV completely.
• Have an honest conversation with sexual partners. HPV is so common that disclosure is informational, not blame — most adults will have been exposed at some point. See Understanding Consent: Empowering Your Choices for the broader frame of open partner communication.
• Consider HPV vaccination even if you have already tested positive. The vaccine still protects you against the strains you have not yet been exposed to — meaningful added protection up to age 45 in many situations.
• See a gynaecologist promptly for abnormal vaginal bleeding (especially after sex), persistent pelvic pain, foul-smelling discharge, new visible bumps, or any Pap or HPV result flagged as abnormal.

• "HPV vaccination encourages promiscuity." Every major study has found no link between HPV vaccination and earlier sexual activity, more partners, or risky behaviour. The vaccine is given before exposure for biological reasons, not as a permission slip.
• "HPV equals STI equals moral failing." HPV is an extremely common viral infection that most sexually active adults will encounter. It says nothing about character, fidelity, or worth. Framing it as a cancer-prevention conversation lifts the shame and opens the door to action.
• "Only women need the HPV vaccine." Boys benefit too. The vaccine prevents anal, penile, throat, and tongue cancers in men, and dramatically reduces household and partner transmission. Indian uptake among boys is even lower than among girls; ask your paediatrician explicitly.
• "If I am married and monogamous, I cannot get HPV." Partial truth. HPV can be carried silently from years ago and surface later, in either partner. Lifelong monogamy lowers risk but does not eliminate it.
• "HPV always becomes cancer." Far from it. 70 to 80 percent of HPV infections clear on their own, and only a small minority of persistent high-risk infections ever become cancer — and even those usually take 10 to 20 years, leaving plenty of time for screening to catch the changes early.
• "HPV transmits via toilet seats, swimming pools, or shared towels." It does not. HPV needs direct skin-to-skin contact with infected genital tissue. Casual contact carries no risk.

• Myth: HPV always becomes cancer. Fact: 70 to 80 percent of HPV infections clear naturally within 1 to 2 years; only a small minority of persistent high-risk infections progress to cancer, and that progression usually takes 10 to 20 years.
• Myth: Only older women get HPV. Fact: HPV is most common in young adults aged 18 to 35; older women are more often the ones in whom persistent infection has had time to progress.
• Myth: The HPV vaccine is only for unmarried women. Fact: The vaccine is licensed and recommended regardless of marital status, including for married women up to age 45 in shared-decision practice.
• Myth: Cervical cancer is rare in India. Fact: India accounts for nearly a quarter of the global cervical cancer burden, with roughly 75,000 deaths every year — almost all of them preventable.
• Myth: HPV transmits via toilet seats. Fact: HPV requires direct skin-to-skin contact with infected genital tissue. Toilet seats, swimming pools, and shared towels are not transmission routes.
• Myth: There is no point getting vaccinated if I already have HPV. Fact: The vaccine still protects against the strains you have not yet encountered, which is most of them in most people.